Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jiutian Chemical Group Limited (C8R.SI)
Singapore, SG
Jiutian Chemical Group Limited, established in Singapore in 1994, operates as an investment holding company with its primary chemical manufacturing and sales activities located in the People's Republic of China. The company's product portfolio encompasses Dimethylformamide (DMF), a vital raw material for polyurethane, pharmaceutical, and agrochemical sectors, also serving as an absorbent in electronics, acrylic fiber production, and pharmaceuticals. They also produce Methylamine, an essential organic chemical feedstock widely used across various industries including agricultural chemicals, medicines, fuels, synthetic resins, and leather processing, as well as in chemical fiber solvents, activating agents, and photography. Another offering is Sodium Hydrosulfite, a crystalline powder with applications in water treatment, gas purification, cleaning, stripping, and industrial processes for textiles, leather, food, polymers, and photography. Furthermore, Jiutian supplies industrial and consumable Carbon Dioxide for aerated drinks, tobacco, and vegetable preservation. Advanced products include Oxygen-18, an oxygen isotope critical for producing fluorodeoxyglucose, and Deuterium Depleted Water, known for its use in inhibiting cancer cell growth, alongside industrial methanol. The group is also involved in the sales of derivative chemical products and conducts research and development in isotope technology.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.35% | -4.35% | -4.35% | -4.35% | -18.52% | -12.00% | +0.00% | -65.08% | -77.55% | +22.22% | -96.59% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%-56.4% Q2'23: -63.9% (vs Q2'21)
-
EPS growth Chemicals: +11.7%-12.0% Q2'23: -172.8% (vs Q2'21)
-
FCF margin FCF growth · Chemicals: +41.7%-155.5% Q2'23: -154.2% (vs Q2'21)
-
EBIT margin Chemicals: +7.1%-124.7% Q2'23: -31.0% (vs Q2'21)
-
ROIC Chemicals: +3.4%-34.8% Q2'23: -44.8% (vs Q2'21)
-
Share dilution Chemicals: +0.0%+0.0% Q2'23: +0.0% (vs Q2'21)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×-1.33× Q2'23: -0.70× (vs Q2'21)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|---|---|---|---|
| Revenue |
1.31B
est: 1.38B (-5.3%)
|
1.05B
est: 1.46B (-27.7%)
|
1.15B
est: 1.16B (-1.3%)
|
2.17B
est: 1.77B (+23.1%)
|
2.43B
est: 2.44B (-0.4%)
|
598.56M
est: 1.87B (-67.9%)
|
243.76M
est: 1.74B (-86.0%)
|
| EBITDA |
69.69M
est: -71.45M (+197.5%)
|
-235.69M
est: -75.38M (-212.7%)
|
274.66M
est: -60.09M (+557.1%)
|
517.79M
est: -91.34M (+666.9%)
|
696.61M
est: -126.38M (+651.2%)
|
-321.76M
est: -96.51M (-233.4%)
|
-118.22M
est: -486.87M (+75.7%)
|
| EBIT |
40.61M
est: -122.97M (+133.0%)
|
-263.52M
est: -129.74M (-103.1%)
|
248.19M
est: -103.42M (+340.0%)
|
488.81M
est: -157.21M (+410.9%)
|
674.29M
est: -217.50M (+410.0%)
|
-344.94M
est: -166.10M (-107.7%)
|
-143.12M
est: -576.86M (+75.2%)
|
| Net Income |
22.08M
est: 10.18B (-99.8%)
|
-248.42M
est: 10.74B (-102.3%)
|
173.69M
est: 217.56M (-20.2%)
|
324.90M
est: 307.79M (+5.6%)
|
490.50M
est: 578.18M (-15.2%)
|
-344.64M
est: 390.35M (-188.3%)
|
-147.80M
est: 346.69M (-142.6%)
|
| SGA |
47.33M
est: 80.13M (-40.9%)
|
46.29M
est: 84.55M (-45.2%)
|
35.59M
est: 67.39M (-47.2%)
|
58.89M
est: 102.44M (-42.5%)
|
62.76M
est: 141.74M (-55.7%)
|
49.09M
est: 108.24M (-54.7%)
|
30.25M
est: 175.51M (-82.8%)
|
| EPS |
0.01
est: 5.12 (-99.8%)
|
-0.14
est: 5.40 (-102.6%)
|
0.09
est: 0.11 (-14.2%)
|
0.16
est: 0.15 (+3.4%)
|
0.25
est: 0.29 (-14.0%)
|
-0.17
est: 0.20 (-186.6%)
|
-0.07
est: 0.17 (-142.6%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chee Seng Lee | Executive Director | 434.0K | male |
| Hongguang Wei | Acting Chief Executive Officer & Group GM of Subsidiaries | 49.0K | male |
| Han Kiat Ng | Group Financial Controller | — | male |
| Qingwu He | Head of Marketing | — | male |
| Wai Ming Chiang | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for C8R.SI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
